Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

SOUTH SAN FRANCISCO, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will present a company update at the C. E. Unterberg, Towbin Emerging Growth Conference on July 12, 2007 at 9:00 a.m. Eastern Time in New York, NY.

Interested parties may access the webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until July 26, 2007.

Option Award Disclosure

The Compensation Committee of the company's Board of Directors approved an employment commencement grant to Mr. Michael Coors, Director, Quality Assurance, of a non-qualified stock option to purchase 25,000 shares of Sunesis common stock, effective June 29, 2007. These option awards were granted without shareholder approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and with the following material terms: (a) an exercise price equal to the fair market value of the company's common stock on the grant date, (b) a term of ten years, and (c) a vesting schedule providing that the option is exercisable as to one-quarter of the total grant on the first anniversary of their hire, and one-forty-eighth of the total grant each month thereafter until the grant is fully vested.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

CONTACT: investors, Eric Bjerkholt, SVP, Corp. Development & Finance ofSunesis Pharmaceuticals, Inc, +1-650-266-3717; media, Karen L. Bergman,+1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners,for Sunesis Pharmaceuticals, Inc.

Web site: http://www.sunesis.com/

Ticker Symbol: (NASDAQ-NMS:SNSS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: July 2007

View comments

Hide
(web2)